IMU is getting international coverage. Even in...

IMU is getting international coverage. Even in Bangladesh.

Imugene (ASX: IMU) up 155% this week - maybe this cancer-killing virus really works? (dhakatribune.com)

Reliable Brokers

OnlineInvesting

Alerts& Analysis

EasyTrading

Imugene (ASX:IMU) up 155% this week - maybe this cancer-killing virus really works?

The results announcedare very early days but there does seem to be evidence of good effects.

https://www.dhakatribune.com/330525

SHAPE \* MERGEFORMAT

ImugeneLimited logo. Photo: Collected

Tribune Financial Markets Desk

Publish: 09 Nov 2023, 03:26 PMUpdate : 09 Nov 2023, 03:26 PM

Advertisement: 0:29

Close Player SHAPE \*MERGEFORMAT

Imugene (ASX: IMU) shares are up 155% this week,36% just today. There seems to be a substantial rerating of IMU shares going on- not just a one day leap but a sustained change the general valuation of thefirm. This is off the back of their announcement about Phase I trials of theirlead drug candidate. Which isn’t in fact a drug, rather a virus which thenattacks cancers.

As they say: “Imugene Ltd (ASX:IMU)(OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinical trialupdate of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluatingthe safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Chongsays the early positive response data being seen at the mid-dose level inhard-to-treat bile duct cancer suggests that VAXINIA may be a potentanti-cancer drug as IMU interrogates higher dose levels.”

Oras the official announcement has it: “Twenty-five patients were evaluable(received at least their first scan at day 42) and seven patients have theirfirst scan still pending. Of the

evaluable patients the BOR (best overall response)are 1 Complete Response (CR), 1

Partial Response (PR), 16 Stable Disease (SD),showing patients had control and

stability of their cancer and 8 progressive disease(PD) as measured by iRECIST*

and RECIST* criteria.Importantly early results from6 patients with gastrointestinal cancers who receivedCF33-hNIS alone including2 colorectal cancer, 2 bile duct, 1 pancreatic and 1 livercancer showedpositive treatment effects, with a disease control rate (all CR, PR

and SD) of 75%.”

There’s a reason all these numbers are so small.You only get to test novel cancer treatments on those who have already used upthe already approved treatments. So, the patient base upon which the newtreatments can be used is pretty small.

SHAPE \* MERGEFORMAT

Imugeneshare price from Google Finance

It’s also worth noting that these are Phase Itrials. There are likely several years yet of further trials to be undertaken.This is not the precursor to imminent revenue. Also, these results are, whilegood, not good enough to simply abandon further testing and roll out thetreatment to all. They’re good but not that good.

So there’s still a long way to go for Imugene butthe basic idea is, at least so far, confirmed. The viral infection does attackthose solid tumours. That is value additive but how far will the market takethis rerating of IMU shares?